AstraZeneca’s Imfinzi Gets Approval In Japan For Extensive-stage Small Cell Lung Cancer

(RTTNews) - AstraZeneca Plc (AZN.L, AZN) announced Friday that its Imfinzi (durvalumab) has been approved in Japan for the treatment of patients with extensive-stage small cell lung cancer or ES-SCLC. SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly, despite initial response to... To keep reading about AstraZeneca’s Imfinzi Gets Approval In Japan For Extensive-stage Small Cell Lung Cancer, Click on the link. Seoul, Korea
http://dlvr.it/Rf3bY9

Comments

Popular posts from this blog

New Philadelphia Digital Agency Makes Its Public Debut

US intel chief rebukes lawmakers over 'pandemic' of leaks

New Data Suggest ExoFlo is Poised for a Quantum Leap in the Fight Against COVID-19